Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Cerebral Edema l: Introduction01:19

Cerebral Edema l: Introduction

Cerebral edema is a pathological increase in brain water content that disrupts intracranial pressure regulation and impairs neurological function. Because the cranial vault is rigid, even modest increases in tissue volume can compromise cerebral perfusion, distort neural structures, and initiate secondary injury. Cerebral edema develops through four principal mechanisms: vasogenic, cytotoxic, interstitial, and ionic.Vasogenic EdemaVasogenic edema arises from disruption of the blood–brain...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Evaluation of a new antihypertensive agent. Minoxidil.

JAMA·1980
Same author

Evaluation of a new uricosuric diuretic--ticrynafen.

JAMA·1979
Same author

Timolol in the treatment of open angle glaucoma.

JAMA·1979
Same author

Evaluation of a new antidiuretic agent, desmopressin acetate (DDAVP).

JAMA·1978
Same author

Evaluation of a new antihypertensive agent: prazosin hydrochloride (Minipress).

JAMA·1977
Same author

Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent.

JAMA·1975
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jul 21, 2026

Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats
08:07

Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats

Published on: August 24, 2016

Lactulosa (cefulac) en la encefalopatía portosistémica.

M E Kosman

    JAMA
    |November 22, 1976
    PubMed
    Resumen

    La lactulosa reduce efectivamente los niveles altos de amoníaco en la sangre y mejora los síntomas en pacientes con encefalopatía portosistémica. Este disacárido sintético es una alternativa segura para prevenir los ataques recurrentes de encefalopatía hepática y mejorar la tolerancia a las proteínas.

    Área de la Ciencia:

    • Hepatología Hepatología.
    • Gastroenterología y Gastroenterología.
    • Farmacología Farmacología.

    Sus antecedentes:

    • La encefalopatía portosystemic (PSE) es una complicación grave de la enfermedad del hígado.
    • Los niveles elevados de amoníaco son un factor clave en el desarrollo de la EPS y la exacerbación de los síntomas.
    • Los tratamientos actuales para la EPS tienen limitaciones y efectos secundarios.

    Objetivo del estudio:

    • Evaluar la eficacia y tolerabilidad de la lactulosa en el tratamiento de la EPE.
    • Para comparar la lactulosa como terapia de mantenimiento frente a otras opciones de tratamiento.
    • Evaluar el impacto de la lactulosa en la tolerancia a las proteínas en pacientes con EPS.

    Principales métodos:

    • Revisión sistemática de ensayos clínicos y estudios observacionales.

    Más Videos Relacionados

    Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
    08:32

    Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

    Published on: January 4, 2018

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
    06:21

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

    Published on: April 7, 2023

    Videos de Experimentos Relacionados

    Last Updated: Jul 21, 2026

    Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats
    08:07

    Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats

    Published on: August 24, 2016

    Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
    08:32

    Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

    Published on: January 4, 2018

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
    06:21

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

    Published on: April 7, 2023

  • Metaanálisis de los niveles de amoníaco, las puntuaciones de los síntomas de PSE y los eventos adversos.
  • Evaluación de los resultados informados por los pacientes y la adherencia al tratamiento.
  • Principales resultados:

    • La lactulosa redujo significativamente los niveles elevados de amoníaco en sangre en pacientes con EPS.
    • Los pacientes que recibieron lactulosa mostraron una mejora marcada en los síntomas de la EPE.
    • La lactulosa fue generalmente bien tolerada con un perfil de seguridad favorable en comparación con las alternativas.

    Conclusiones:

    • La lactulosa es un tratamiento eficaz y seguro para reducir el amoníaco y mejorar los síntomas de la EPS.
    • Sirve como una alternativa adecuada al sulfato de neomicina para el manejo a largo plazo de la EPS.
    • La terapia con lactulosa puede prevenir los ataques recurrentes de EPS y mejorar la tolerancia a las proteínas.